Skip to content

Fontan-Sprechstunde

Prospektive Erfassung Von standardmäßig Erhobenen Daten im Rahmen Der Erlanger Fontan-Sprechstunde Zur Behandlung Und Überwachung Von PatientInnen Mit univentrikulärem Herzfehler im Sinne Einer Fontan-Zirkulation

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05563376
Enrollment
200
Registered
2022-10-03
Start date
2020-09-01
Completion date
2041-09-01
Last updated
2022-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Univentricular Heart

Brief summary

After successful Fontan surgery, the risk of mortality in childhood is only low. Unfortunately, some of the patients suffer from Fontan-typical long-term complications in the long-term course, whereby protein loss neuropathy must be mentioned in particular, which is described in the literature with an incidence of 3-14% (1, 2) and still has a 5-year risk of death of 6-12% today (2, 3). Protein loss tereopathy leads to loss of protein in the intestine and subsequently to diarrhea and edema. Other problems concern the liver, which can develop cirrhosis due to chronic congestion (4-6). Cardiac can lead to heart failure and arrhythmias. The registry study described in this protocol is intended to identify factors that influence the treatment outcome of patients in the Fontan circulation in the long term through systematic prospective documentation of the data from our standardized and guideline-oriented treatment.

Detailed description

In particular, the following points will be scientifically analyzed: 1. The development of lymphatic drainage disorders (7-9) 2. The cellular changes of the immunological system and metabolome (10) In addition to the clinical routine, weight-adapted EDTA blood for the isolation of peripheral blood mononuclear cells (PBMCs) for the scientific investigation of immunological changes and serum for the analysis of the metabolome will be examined at three times (Figure 1: Times 2, 4, 7) as part of a routine blood sample (10). 3. The recording and treatment of psychological, social and developmental abnormalities with the help of standardized questionnaires. 4. The evaluation of special sonography examinations of the liver and kidney in the long-term course, as well as their treatment. 5. The assessment of the hemodynamic peculiarities and the classification with regard to Cardiac function in the long-term course of patients with Fontan circulation. 6. The assessment of various laboratory parameters as risk parameters for the development of complications. 7. The recording of cardiopulmonary performance in the long-term course and its ability to be influenced by education regarding sporting activity and the handing over of an individualized training plan. 8. The influence of physical activity on possible complications of Fontan circulation. 9. The influence of early psychological, nutritional, or social intervention in the event of abnormalities on later complications of Fontan circulation.

Interventions

DIAGNOSTIC_TESTUniventricular Hearts

Prevention when factors are recognized

Sponsors

University of Erlangen-Nürnberg Medical School
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
6 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* congenital heart defect of the univentricular type that has led to Fontan circulation

Exclusion criteria

* no

Design outcomes

Primary

MeasureTime frameDescription
Reducing mortality and morbidity and improving quality of life in long-term care for Fontan patients50 Jahre1. Fontan Tunnel Obstruction 2. Fontan-typical klin. Symp. defined in points 5.+6. o. Presence of edema, ascites, susceptibility to infections, reduced resilience, cyanosis, lack of size and weight development, diarrhea 3. Heart or heart valve insufficiency defined as end-diastolic volume/BSA (EDP corrected) above the norm, ventricle ejection fraction (EF) \<50%, atrioventricular heart valve insufficiency (AVI) \>grade 2, aortic valve insufficiency \>grade 2 4. Pathological lymphatic vessel imaging defined as lymphatic vasodilation (LAE) type ≥ 3 according to Biko et al. (abnormal supraclavicular lymphatic vasodilation with infiltration of the mediastinum) (7). Presence of mesenteric lymphatic vascular congestion (8) 5. Hypoproteinaemia defined as serum albumin \<3.4 mg/dl (4), total protein (TP) \<50 g/l 6. protein-losing enteropathy (PLE) defined as (3, 4) 7. Failing Fontan defined as Operative Fontan Take-down, Listing for Heart Transplantation and/or Death

Countries

Germany

Contacts

Primary ContactIsabelle Schöffl, PD
isabelle.schoeffl@uk-erlangen.de09131 85 33750
Backup ContactSven Dittrich, Prof.
sven.dittrich@uk-erlangen.de09131 85 33750

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026